Clinton discusses global HIV efforts with South African officials during 11-day African tour

NewsGuard 100/100 Score

U.S. Secretary of State Hillary Clinton on Tuesday visited officials in South Africa and discussed the response to HIV/AIDS, the Associated Press/Huffington Post reports. Speaking with Foreign Minister Maite Nkoana-Mashabane "in the second cabinet-level strategic dialogue between the two nations," Clinton said "that global efforts to stop the virus 'have saved hundreds of thousands of lives,'" the news service writes. "In South Africa, 5.7 million people -- 17.8 percent of the population -- have tested positive for HIV," and PEPFAR "has spent $3.2 billion on antiretroviral drugs and HIV prevention programs in [the country] since 2004," according to the AP.

"On Wednesday in Cape Town, Clinton will preside at a ceremony at which the U.S. will begin shifting administrative control of [some PEPFAR-funded programs] to the South Africans," a handover that will take five years, according to the news service. "Clinton is in South Africa at the midpoint of an 11-day tour that has already taken her to Senegal, Uganda, South Sudan, Kenya and Malawi," the AP notes (Lee, 8/7).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Unveiling the key role of RNA modification in HIV-1 survival and replication